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Background: In end-stage heart failure (HF), the implantation of a left ventricular assist device (LVAD) is able to
induce reverse remodeling. Cellular proteases, such as cathepsins, are involved in the progression of HF. The aim of
this study was to evaluate the role of cathepsin system in HF patients supported by LVAD, in order to determine
their involvement in cardiac remodeling.
Methods: The expression of cysteine (CatB, CatK, CatL, CatS) and serine cathepsin (CatG), and relative inhibitors
(Cystatin B, C and SerpinA3, respectively) was determined in cardiac biopsies of 22 patients submitted to LVAD
(pre-LVAD) and compared with: 1) control stable chronic HF patients on medical therapy at the moment of heart
transplantation without prior LVAD (HT, n = 7); 2) patients supported by LVAD at the moment of transplantation
(post-LVAD, n = 6).
Results: The expression of cathepsins and their inhibitors was significantly higher in pre-LVAD compared to the HT
group and LVAD induced a further increase in the cathepsin system. Significant positive correlations were observed
between cardiac expression of cathepsins and their inhibitors as well as inflammatory cytokines. In the pre-LVAD
group, a relationship of cathepsins with dilatative etiology and length of hospitalization was found.
Conclusions: A parallel activation of cathepsins and their inhibitors was observed after LVAD support. The possible
clinical importance of these modifications is confirmed by their relation with patients ? outcome. A better discovery
of these pathways could add more insights into the cardiac remodeling during HF.
Keywords: Cathepsin system, Cardiac remodeling, Heart failure, LVAD therapyBackground
According to data from the American Heart Association
(AHA) community surveillance component of the Athero-
sclerosis Risk in Communities (ARIC) study of the National
Heart, Lung, and Blood Institute (NHLB1), the prevalence
of HF will increase by 46% from 2012 to 2030, resulting in
more than 8 million people ≥18 years of age with HF [1].
Implantation of left ventricular assist device (LVAD) has be-
come a new gold standard to support end-stage HF (ESHF)
patients as a bridge to heart transplantation [2]. LVAD* Correspondence: chiara.caselli@ifc.cnr.it
2Laboratory of Cardiovascular Biochemistry, Institute of Clinical Physiology,
Consiglio Nazionale delle Ricerche (CNR), Area della Ricerca ? Via Moruzzi, 1,
56100 Pisa, Italy
Full list of author information is available at the end of the article
? 2014 D'Amico et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.support has been shown to affect myocardial remodeling,
which is a complex pathologic process of ultrastructural re-
arrangement of the heart typically observed in chronic HF;
it also sometimes promotes partial recovery of ventricular
function, a process known as reverse remodeling [3]. In this
process, alterations of the extracellular matrix (ECM) have
a central role, and modulations of the activities of different
proteases have become a topic of great interest [4]. Recent
evidence supports the hypothesis that other proteases, such
as calpains and cathepsins [5], may be involved in heart
remodeling [4]. Among these, cathepsins have been the
recent focus of several studies, owing to their emerging role
in different diseases [6,7].
Since 1920, the term ? cathepsin ? stands for lysosomal-
proteolytic enzyme regardless of the enzyme class [6].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and integrity but today they are believed to be impli-
cated in the development and progression of cardiovas-
cular disease [5]. This term includes serine proteases
(cathepsins A and G), aspartic proteases (cathepsin D
and E) as well as the better-known cysteine cathepsins
(cathepsins B, C, F, H, K, L, O, S, V, X and W), as reported
in Table 1. Cysteine cathepsins are typically known as
housekeeping proteases essential for cardiac function; they
are ubiquitous and contribute to distinct physiologic pro-
cesses [5,7]. They are strictly regulated intracellularly
by specific endogenous inhibitors belonging to the
cystatin subgroup, cystatin A (CysA) and B (CysB) (also
known as stefins A and B, respectively) and extracellu-
larly by cystatin C (CysC) and kininogens [6,8,9]. Serine
cathepsins are a key component of the inflammatory
response as they are released from activated leukocytes
and mast cells (MCs). The main representative cathep-
sin of this group is cathepsin G (CatG), which can
modulate biological functions through the processing
of chemokines, modulation of the cytokine networkTable 1 Cathepsin classification
Cathepsin Cytosolic substrates Function
Serine protease
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and beta-na
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Cathepsin V elastolytic activity Production o
Cathepsin W Cell-mediate
Cathepsin X Phagocytosi
Cathepsin Z Protein degand the activation of specific cell surface receptors, es-
pecially in the heart [10]. CatG is regulated by the Ser-
pin peptidase inhibitor A3 (SrpA3), a widely expressed
member of the serpin superfamily, also released during
the inflammatory response [11].
Emerging evidence shows serine and cysteine cathep-
sin involvement in cardiac remodeling occurring in HF
[5,17]. However, few data are available relative to cathep-
sin expression in cardiac tissue of ESHF patients and
there are no reports on the effect of LVAD support in
patients submitted to LVAD as a bridge to transplant-
ation. The aim of this study was to evaluate the cathep-
sin system in cardiac tissue of ESHF patient candidates
for LVAD implant compared to: 1. control stable chronic
HF patients on medical therapy at the moment of heart
transplantation without prior circulatory support; 2. pa-
tients supported by LVAD at the moment of transplant-
ation. For this, expression of the main cysteine and
serine cathepsins as well as their specific inhibitors was
determined in cardiac tissue obtained from the three
groups of ESHF patients.Specific inhibitor Ref
plex mediated inflammation,









bolism, processing of antigens
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Patients and study design
Cardiac biopsies were obtained from ESHF patients sup-
ported by LVAD implant as a bridge to heart transplant-
ation. Tissue samples were harvested from twenty-two
patients at the moment of LVAD implantation from the
apex of native heart (pre-LVAD group, n = 22). All these
patients were supported by axial continuous-flow devices
[16 were HeartMateII LVAD (Thoratec, Pleasanton, CA,
USA), 4 were Incor LVAD (Berlin Heart AG),1 was De
Bakey LVAD (MicroMed Technology Inc., Houston, TX,
USA), and 1 was HeartWare LVAD (HeartWare Inter-
national Inc., Framingham, MA, USA)].
In order to assess the effects of LVAD support on ca-
thepsin systems the pre-LVAD group was compared with
two other groups:
? A control group of seven ESHF patients supported
by pharmacological therapy who directly went to
heart transplantation without mechanical support. A
total of thirty-five biopsies were collected at the
moment of heart transplantation from pre-specified
areas from the left ventricle (LV) (anterior basal,
lateral basal and apex myocardial specimens) and
from the right ventricle (RV) (anterior basal and the
lateral basal myocardial specimens) as previously
reported [20] (HT group, n = 35);
? A group of six patients supported by LVAD as
bridge to transplantation. Cardiac biopsies (n = 30)
were collected at the moment of the mechanical
device explant from the same pre-specified areas of
the control group [20]. Five patients were supported
by axial continuous-flow devices [three were De
Bakey LVADs (MicroMed Technology Inc.), one
was a HeartMate II LVAF (Thoratec)] and one
patient was supported by a pulsatile-flow device
(NewCrTec, Rome, Italy). A total of thirty biopsies
were collected at the moment of heart transplantation
[20] (post-LVAD group, n = 30).
Immediately after collection, myocardial samples were
frozen in liquid nitrogen and stored at ? 80?C until sam-
ple preparation.
Clinical parameters such as vital status and NYHA
functional class were evaluated in all patients, both at
admission and during LVAD support. In addition, the
overall condition of multi-organ function was daily mon-
itored according to the Sequential Organ Failure Assess-
ment (SOFA). The SOFA system is a daily score from 0
to 4 assigned in proportion to the severity of functional
deterioration for each of six individual organ systems
(cardiovascular, respiratory, hepatic, renal, neurological,
and hemocoagulative) [21]. The clinical course of these
patients was assessed considering the following end-points: tSOFA score at 1 week, length of intensive care
unit (ICU) stay, hospitalization, and 3-month survival.
The combination of postoperative tSOFA score ≥11 and/
or ICU death was taken into account as main composite
adverse outcome during ICU stay.
Ethics statement
The study conformed the principles outlined in the Dec-
laration of Helsinki and the study protocol was approved
by Niguarda C? Granda Hospital ethics committee (176/
2005). All subjects gave written informed consent to par-
ticipate to the study.
Inclusion and exclusion criteria for patient enrolment
Enrolment criteria for the LVAD implant were: idio-
pathic dilated/ischemic cardiomyopathy, not amenable
to recovery by pharmacological or conventional surgical
therapy; INTERMACS profile 1, 2 and 3 [22]; LVEF <
25%; peak oxygen consumption < 12 mL/Kg/min; body
surface area > 1.5 m2; urgent heart transplantation not
feasible; lack of contraindications for LVAD implanta-
tion; acceptable overall operative risk. Exclusion criteria
were: irreversible renal/hepatic failure due to pre-existing
chronic hepato-renal disease; severe diabetes mellitus with
end-organ damage; severe peripheral vascular disease;
coexisting active neoplasm; pregnancy; recurrent alcohol
and drug abuse, and cognitive impairment severe enough
to limit comprehension. As to the HT group, ESHF pa-
tients matched for age, sex, diagnosis and NYHA classes
with pre-LVAD group were enrolled as control group.
mRNA extraction and cDNA synthesis
Total RNA was extracted from heart samples with the use
of the acid guanidiniumthiocyanate-phenol-chloroform
method thanks to a Rneasy Midi kit (QiagenS.p.a, Milano,
Italy) as described by the manufacturer. RNA concentra-
tion and purity were evaluated spectrophotometrically
(BioPhotometer Eppendorf, Milan, Italy) and by electro-
phoresis of samples on Gel Star Stain (Lonza Rockland
Inc., ME, USA) agarose gels. Only samples with spectro-
photometric 260/280 nm ratios of 1.8? 2.1 and clear 28S
and 18S ribosomal RNA bands resulting from electrophor-
esis were used. A known amount of total RNA (Ambion,
Inc., Austin, TX, USA) was used as marker. The RNA
samples were stored at ? 80?C for use in gene expression
studies.
Following DNAse treatment (RNase-Free DNase Set,
QiagenS.p.A), first-stand cDNA was synthesized by IScript
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules,
CA, USA) starting from about 1 μg total RNA as template.
Reverse transcriptase reaction sequence consisted of an
incubation step at 25?C for 5 min, followed by three dif-
ferent cycles at 42?C for 30 min and 45 ? 48?C for 10 min,
in order to better separate the strands. The reverse
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for 5 min. The cDNA samples obtained were placed on
ice and stored at 4?C for a maximum of 1 month.
Real-time PCR
ProbeFinder 2.5 (Roche Applied Science) was used for
designing primers. Real-time PCR reactions were per-
formed in duplicate in the Bio-Rad C1000 thermal cycler
(CFX-96 Real-Time PCR detection systems; Bio-Rad)
using Eva-Green (SsoFASTEvaGreenSupermix; Biorad),
a third-generation fluorophore, in order to monitoring
cDNA amplification. PCR was performed in a volume of
20 μl/reaction; to minimize the influence of PCR inhibi-
tors in real-time applications, all cDNA samples were di-
luted 1:10. Reaction mixture included 2 μl template cDNA
(10 ng/ml), 0.2 mM of each primer (Sigma-Aldrich), 1X
SsoFASTEvaGreenSuperMix (Bio-Rad), and sterile H2O.
To assess product specificity, amplicons were systematic-
ally checked by melting curve analysis. Melting curves
were generated from 65? 95?C with increments of 0.5?C/
cycle. Multiple inter-run calibrators were always used to
allow comparison of Ct values obtained in different runs.
The reaction conditions of all primer pairs used were set
out. In order to assess the optimal annealing temperature
a gradient PCR was conducted while to verify efficiency aTable 2 Analytical details of gene primers for real-time PCR a
Sequence GenBank, ac
CAT-G Forward TGACTGACTCTTCTTCTC NM_001911.2
Reverse AGGAATTGGTTATTTATACTCT
CAT-B Forward CTGTGGCAGCATGTGTGG NM_001908.3
Reverse GCACCCTACATGGGATTCAT
CAT-L Forward GGGAGGGCAGTTGAGGAC NM_001912.4
Reverse GCAAGGATGAGTGTAGGATTCA
CAT-K Forward GCCAGACAACAGATTTCCATC NM_000396
Reverse CAGAGCAAAGCTCACCACAG
CAT-S Forward GCTGAGGCACGAGATTCC NM_004079
Reverse AGTCTCCACTCTGTCATCCA
CYS-B Forward GAGTCCCCTCGCCAGATT NM_000100.2
Reverse AACACAGGGAACTTCTTGTTTTCT
CYS-C Forward AGGAGACAGACAGAGAAG NM_000099.2
Reverse TATGAGAAGCAAGAAGGAA
SRPA3 Forward ACTCCAGACAGACGGCTTTG NM_001085.4
Reverse ATTCTCTCCATTCTCAACTCTGC
YWHAZ Forward ATGCAACCAACACATCCTATC NM_0011357
Reverse GCATTATTAGCGTGCTGTCTT
PPIA Forward CTTGGGCCGCGTCTCCTTCG NM_021130
Reverse TTGGGAACCGTTTGTGTTTGGGGC
RPL13A Forward CGCCCTACGACAAGAAAAAG NM_012423
Reverse CCGTAGCCTCATGAGCTGTTstandard curve, obtained by scalar dilution of a cDNA
pool (1:5, 1:25, 1:125, and 1:625), was always generated.
We adhered to the Minimum Information for Publication
of Quantitative real-time PCR Experiments (MIQEs) guide-
lines [23] to increase the reliability and integrity of study
results and to promote efforts for experimental consistency
and transparency between research laboratories.
The parameters derived from real-time PCR analysis
required by MIQE guidelines are reported in Table 2.
Data analysis
The geometric mean of the three most stably expressed
genes (YWHAZ, RPL13A and PPIA) previous settled in
our laboratory [20], was used for normalization of real-
time PCR results.
The relative quantification was performed by ΔΔCt
method using Bio-Rad ? s CFX96 manager software
(CFX-96 Real-Time PCR detection systems, Bio-Rad
Laboratories Inc.).
Data are expressed as mean and mean standard error
(SEM). Variables were not normally distributed and were
logarithmically transformed. Student? s t-tests (for com-
parisons between two groups) or ANOVA (for compari-
son of two or three groups) followed by Tukey post hoc
tests were used to analyze the differences among groups.nalysis
cession # Length (bp) Temp (?C) Efficiency (%) R2
91 55 108.7 0.997
115 60 107.5 0.998
111 64.5 98.5 0.995
75 60 108.1 0.999
78 60 103.8 0.996
149 60 104 0.994
84 58 95.2 0.998
73 60 100.5 0.995
2 178 60 95.3 0.997
285 60 103.4 0.998
206 60 104.6 0.999
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to analyze the relationship between variables. A 2-tailed
p-value <0.05 was considered statistically significant.
Results
Patient characteristics
Patient characteristics are reported in Table 3. Clinical
features were compared according to the previously de-
scribed experimental groups (pre-LVAD, HT and post-
LVAD group).
Pre-LVAD and HT group
Median age of LVAD candidates (pre-LVAD group) was
comparable to that of patients who underwent elective
HT on medical therapy, without prior circulatory sup-
port (HT group). Idiopathic dilatative cardiomyopathy
(IDC) was prevalent in both groups. Echocardiographic
parameters as well as medical therapies did not differ be-
tween pre-LVAD and HT patients; anti-platelet and anti-
coagulant agents, which were mandatory in pre-LVAD
patients, were prevalent in pre-LVAD group. Total bili-
rubin and creatinine values did not show differences be-
tween the pre-LVAD group and HT group.Table 3 Clinical features of ESHF patients according to sampl
Pre-LVAD (n = 22) HT Patient (n =
Age, years 58 (48? 64) 55 (46? 62)
Male gender, n (%) 19 (86) 5 (71)
Etiology, n (%) - -
IDC 12 (55) 6 (86)
IHD 10 (46) 1 (14)
Treatments, n (%) - -
ACE-I and/or ARB 13 (59) 5 (71)
Beta-blockers 16 (80) 5 (71)
Statins 6 (27) 2 (29)
Antiplatelet agents 12 (54) 2 (29)
Inotropic support 11 (50) 1 (14)
Creatinine, mg/dL 1.08 (0.9-1.53) 1.32 (1.00-1.78)
t-Bil, mg/dL 1.43 (0.55-1.90) 0.76 (0.48-1.14)
NT-proBNP, ng/L 2838 (1371? 6042) 2389 (840? 5762
LVEF, % 23 (19? 25) 28 (20? 29)
LVEDV, mL 202 (173? 291) 228 (206? 300)
LVEDD, mm 67 (57? 71) 70 (68? 79)
RAP, mmHg 5 (3 ? 10) 3 (2? 5)
PCWP, mmHg 25 (17? 31) 11 (4? 20)
CI, L/min/m2 1.7 (1.4-2.2) 2.0 (1.5-2.7)
PAPs, mmHg 55 (42? 63) 28 (19? 42)
Data are expressed as median (25th-75th percentile) or frequency (percentage). ACE, a
index; IDC, idiopathic dilated cardiomyopathy; IHD, ischemic heart disease; LVEDD, left
LVEF, left ventricular ejection fraction; PAPs: pulmonary systolic arterial pressure; PCWP
P Value* pre-LVAD group vs HT group; P Value? pre-LVAD group vs post-LVAD group; ?Pre- and post-LVAD patients prior to heart transplantation
Among the post-LVAD group, the median support time
prior to heart transplantation was 367 (152 ? 483) days.
Median age of patients of post-LVAD group was lower
than that of patient from pre-LVAD group. At heart
transplantation, in patients of post-LVAD group, the
levels of cardiac index, right atrial pressure, pulmonary
capillary wedge pressure, as well as of NT-proBNP were
lower than those of the pre-LVAD group, and compar-
able to those of HT group patients.
Postoperative LVAD outcome
After LVAD implantation, all pre-LVAD patients experi-
enced postoperative hemodynamic improvement with
respect to that at pre-implant (data not shown). At 3
postoperative months, 4 out of 22 (18%) pre-LVAD pa-
tients had died, in particular during ICU stay (second
and third postoperative week), with multi-organ failure
syndrome (MOFS) as main cause of death. Among sur-
vivors, the ICU length of stay was 14 [9-12,15-18,21-27]
days, while hospitalization was of 45 (30 ? 67) days. In all
patients, the tSOFA score at 1 postoperative week was
higher than that at pre-implant [9 (4 ? 10) and 4 (2 ? 5),e groups
7) P Value* Post-LVAD (n = 6) P Value?
0.459 44 (41? 51) 0.031





0.677 4 (67) 1.000
0.633 4 (67) 0.596
1.000 - 0.284
0.390 6 (100)? 0.062
0.187 2 (33) 0.655
0.313 0.95 (0.83-1.48) 0.599
0.212 0.79 (0.62-1.35) 0.199
) 0.522 599 (158? 1036) 0.007
0.220 32 (20? 33) 0.104
0.185 237 (178? 260) 0.820
0.132 68 (60? 75) 0.633
0.074 3 (2? 6) 0.969
0.019 10 (3? 13) 0.023
0.362 3.0 (2.2-3.3) 0.085
0.012 29 (21? 33) 0.006
ngiotensin converting enzyme; ARB; angiotensin receptor blockers; CI, cardiac
ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume;
, pulmonary capillary wedge pressure; RAP, right atrial pressure; t-Bil, total bilirubin;
P <0.05 vs HT group.
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enced severe multi-organ failure evidenced by postoper-
ative tSOFA score ≥11. Overall, nine out of 22 patients
(41%) experienced postoperative tSOFA score ≥11 and/
or ICU-death, together considered as composite critical
outcome.Cathepsin expression in myocardial samples
The mRNA expression of cathepsins and inhibitors was
compared according to the experimental groups, the
pre-LVAD, HT and post-LVAD group and reported in
Figures 1, 2, and 3.At baseline
The cathepsin system was evaluated in myocardial speci-
mens of ESHF patients at the moment of LVAD implant-
ation (pre-LVAD group) and compared with a group of
stable HF patients subjected to heart transplantation as
control (HT group).
Cardiac mRNA expression of CatL resulted signifi-
cantly higher in the pre-LVAD group than in the control
group (HT group) (Figure 1). Similarly, the levels of the
related cathepsin inhibitors CysB and CysC were signifi-
cantly higher in the pre-LVAD group than in the HT
group (Figure 2). Regarding serine cathepsins, both CatG
and SrpA3 showed no significant variation in the pre-
LVAD compared to HT group (Figure 3).Figure 1 Cysteine cathepsins. mRNA expression of cysteine cathepsins in c
group (n=35) and post-LVAD group (n=30), respectively. Relative expressionsNo correlation was observed between Cathepsin sys-
tem and clinical characteristic of patients, including clas-
sical risk factors, echocardiographic parameters, and
medications. As depicted in Figure 4, cardiac SrpA3 was
able to identify the etiology of HF among clinical fea-
tures of the pre-LVAD group, since they were signifi-
cantly higher in IDC than IHD patients.
After LVAD implant
The effect of LVAD support on cathepsin systems was
evaluated at tissue level by comparison of the pre-LVAD
group with a group of patients at the time of heart trans-
plantation (post-LVAD group). As for the cysteine ca-
thepsin system, only CatS showed a significant increase
in the post-LVAD compared with the pre-LVAD group
(Figure 1) while in the serine cathepsin system both CatG
and the inhibitor SrpA3 were significantly higher in post-
LVAD (Figure 3). Cardiac mRNA transcripts of CatL,
CatS, and CatG, and respective inhibitors resulted signifi-
cantly higher in the post-LVAD group compared to their
respective levels in the HT group (Figures 1, 2, and 3).
Relationship between cathepsins and inhibitors
Significant positive correlations were observed between
the cardiac expression of cathepsins belonging to differ-
ent classes and their specific inhibitors, as shown in
Table 4. In particular, a strong correlation between CatS
and CatG was observed; both of them showed again aardiac tissue from ESHF patient of pre-LVAD group (n=22), HT control
(mean value ? SEM) of CatB (A), CatL (B), CatS (C) CatK (D) are shown.
Figure 2 Cysteine cathepsin inhibitors. mRNA expression of cysteine cathepsin inhibitors in cardiac tissue from ESHF patient of pre-LVAD
group (n = 22), HT control group (n = 35) and post-LVAD group (n = 30), respectively. Relative expression (mean value ? SEM) of CysB (A) and
CysC (B) are shown.
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relation was observed between cysteine cathepsins, such
as CatB, CatL and CatK, as well as their inhibitors (CysC
and CysB).
Cathepsins and inflammatory markers
Classic inflammatory markers IL-6, IL-8 and TNF-α were
determined in cardiac samples from HT- pre-LVAD and
post-LVAD groups (Table 5), as previously reported
[20,24]. mRNA expression of IL-6 and IL-8 were higher in
the post-LVAD group compared to LVAD candidate and
HT groups. TNF-α mRNA expression was higher only in
pre-LVAD group compared to post-LVAD group.
Relationships between cathepsin system and inflamma-
tory markers were reported in Table 6. Cathepsins and
their inhibitors positively correlate with IL-6. Only the
serine cathepsin CatG and its specific inhibitor SrpA3 cor-
related with IL-8. Conversely, cysteine cathepsins CatL
and CatB showed a positive correlation with TNF-α.
Cathepsins and outcome indices
The clinical course of ESHF (pre-LVAD group) was eval-
uated considering the outcome indices. CatS and CatKFigure 3 Serine cathepsin system. mRNA expression of serine cathepsin s
HT control group (n = 35) and post-LVAD group (n = 30), respectively. Relativas well as SrpA3, assessed at pre-implant, showed a positive
correlation with length of hospitalization (Figure 5). No sig-
nificance was found with the other outcome indices.
Discussion
This study shows for the first time that ESHF patient can-
didates for LVAD implant present higher expression levels
of CatB and CatL as well as their specific inhibitors, CysB
and CysC, compared to less severe HF patients undergoing
medical therapy (HT group). In addition, modifications of
cathepsin system, including CatS and CatG and its specific
inhibitor, SrpA3, are influenced by mechanical unloading
through LVAD support. A significant relationship with the
length of hospitalization for CatS, CatK and SrpA3 at base-
line was also observed, suggesting the relevance of this sys-
tem regarding patient outcome.
In particular, before LVAD implantation CatL and
CatB showed significantly higher mRNA levels com-
pared to more stable patients who received transplants
without LVAD support. These data are in tune with pre-
vious reports indicating that the cathepsin system is in-
volved in cardiovascular function [5-7] and especially in
HF progression [15,17] and hypertrophy [18]. Chengystem in cardiac tissue from ESHF patients of pre-LVAD group (n = 22),
e expressions (mean value ? SEM) of CatG (A) and SrpA3 (B) are shown.
Figure 4 SrpA3 and HF etiology in pre-LVAD patients. IDC:
Idiopathic dilatative cardiomyopathy; IHD: ischemic heart disease.
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CatK was markedly increased throughout the myocar-
dium of both rats and humans during HF, while only a
low level of expression of these enzymes was observed
in the myocardium of controls. Hua Y et al. [18], re-
ported that in a knockout mice model the lack of CatK
is associated to protective action inducing resistance to
pressure overload ? induced cardiac hypertrophy, fibrosis,
and contractile anomalies. The mRNA expression levels
of cysteine cathepsins, CatS, CatB, and CatK, increased
in atherosclerotic plaque and in failing rat myocardium
[16,25]. An important role in the regulation of apoptosisTable 4 Correlation among members of cathepsin system
CatB CatL CatK CatS
CatB ? rho = 0.51 rho = 0.50 rho = −0.14
p = 0.0006 p = 0.0009 ns
CatL ? rho = 0.46 rho = 0.12
p = 0.0011 ns






SrpA3and immunoregulation was suggested for CatB [14].
Jiang H et al., report that CatK plays important roles
in pathobiology of cardiovascular tissues in vivo and
in vitro models [26]. Cathepsin inhibition also results in
vascular cardioprotection via the reduction of inflamma-
tion and smooth muscle cell proliferation [14,27]. These
evidences suggest an important involvement of cathepsin
system in several molecular mechanisms underlying car-
dioprotective pathways.
At present, no data comparing cathepsin expression
before and after LVAD support are available. Our results
showed that the cathepsin cardiac system is activated
after mechanical support. Different behaviour between
both cysteine and serine cathepsins, and their specific in-
hibitors was observed after LVAD implant, pointing out a
diverse pattern of expression of these classes of cathepsins.
In particular, mRNA expression levels of cysteine cathep-
sins (CatB, CatL and CatK) and their specific inhibitors
(CysB and CysC) were no modified after LVAD implant,
while mRNA expression levels of serine cathepsin (CatG)
and its specific inhibitor (SrpA3) showed a parallel signifi-
cantly increase. Among cysteine catepsins, only CatS was
modified by LVAD support. CatS appears to be involved in
the development of various pathological conditions such
as cardiovascular disease, obesity, and inflammatory dis-
eases [19]. CatG is known to be a serine protease released
from neutrophils [10] and MCs associated with inflamma-
tory processes [28-31] and HF progression [31-33]. CatG
concentration and activity were reported to decrease
along with the reduction of inflammation and MC pro-
inflammatory-type concentration [28]. After LVAD sup-
port, inflammatory cytokines remained significantly highCysC CysB CatG SrpA3
rho = 0.42 rho = 0.32 rho = −0.17 rho = 0.26
p = 0.0032 p = 0.027 ns ns
rho = 0.38 rho = 0.43 rho = −0.01 rho = 0.15
p = 0.0057 p = 0.0019 ns ns
rho = 0.35 rho = 0.29 rho = 0.24 rho = 0.41
p = 0.0128 p = 0.037 ns p = 0.0031
rho = 0.44 rho = 0.36 rho = 0.73 rho = 0.68
p = 0.0023 p = 0.01 p <0.0001 p < 0.0001
? rho = 0.70 rho = 0.40 rho = 0.36
p < 0.0001 p = 0.0038 p = 0.007
? rho = 0.24 rho = 0.16
ns ns
? rho = 0.62
p < 0.0001
?
Table 5 mRNA expression levels of IL-6, IL-8 and TNF-α according to patient groups
Pre-LVAD (n = 22) HT Patient (n = 7) P Value* Post-LVAD (n = 6) P Value?
Interleukin-6 0.038 (0.021-0.089) 0.016 (0.006-0.034) 0.0027 0.595 (0.141-0.706) <0.0001
Interleukin-8 0.010 (0.007-0.015) 0.041 (0.008-0.164) 0.0267 0.478 (0.237-0.901) <0.0001
TNF-α 0.165 (0.101-0.393) 0.109 (0.064-0.646) 0.981 0.468 (0.175-0.828) 0.0166
Data are expressed as median (25th-75th percentile).
P Value* pre-LVAD group vs HT group; P Value ? pre-LVAD group vs post-LVAD group.
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inflammatory cytokines and cathepsins has been shown in
HF [5]. In vitro, mRNA expression of CatS, CatB, CatL,
and CatK increase in neonatal cardiac myocytes in re-
sponse to the inflammatory cytokines, identifying cardiac
myocytes as a potential source of cathepsins [4]. TNF-α
and IL-1β markedly cause the increase of cathepsin genes
and protein expression in cardiomyocytes [5]. In agree-
ment with these observations, in our study a positive
correlation of cathepsins with inflammatory cytokines was
observed, suggesting a possible influence of the inflamma-
tory environment after mechanical support by LVAD on
mRNA expression levels of cathepsins.
A recent hypothesis suggests that temporally regulated
activation and suppression of inflammation may be crit-
ical for achieving effective cardiac repair and regener-
ation, indicating a paradoxical role for inflammation
[34]. Similarly, some evidence points out the possible
positive involvement of cathepsins in cardiac repair [17].
In our study mRNA expression profile of all cathepsins,
except for CatK, was higher in patients supported by
LVAD than HT group. In particular, CatL mRNA expres-
sion profile, which is known to be implicated in cardiac
repair [5,35,36], was significantly higher in patients from
pre- and post-LVAD groups than HT group, suggesting a
possible involvement in cardiac remodeling.
In this study the cellular cathepsin specific inhibitors
were also evaluated. The mRNA expression of CysC and
CysB, the extracellular and intracellular cysteine cathep-
sin inhibitors respectively, resulted higher both before
and after LVAD support compared to HT group in paral-
lel with the increase of CatL. Decreased CysC expression
is generally associated with an increased incidence ofTable 6 Correlation between cathepsins and inflammatory m
CatS CatL CatB
IL-6 rho = 0.43 rho = 0.37 rho = 0.32
p = 0.003 p = 0.007 p = 0.025
IL-8 rho = 0.21 rho = −0.07 rho = 0.02
ns ns ns
TNF-α rho = −0.20 rho = 0.30 rho = 0.44
ns p = 0.049 p = 0.007atherosclerosis and with severity of cardiovascular
disease [37]. High plasma concentrations of CysC were
independently associated with cardiovascular risk factors
[8]. Moreover, in our study SrpA3, inhibitor of CatG,
showed a significant increase in post-LVAD patients
compared to pre-LVAD and HT patients and positively
correlated with CatG and CatS. No data are available re-
garding SrpA3 involvement in HF especially in patients
with mechanical support. SrpA3, mainly expressed in
endothelial cells, is required for the regulation of several
other proteases derived from MCs and neutrophils
during the inflammatory response [11]. It is known that
low SrpA3 expression levels were associated with an in-
creased risk for atherosclerosis and aneurysm formation
[12]. High mRNA expression of SrpA3 observed both
after LVAD support and in IDC patients could suggest a
possible involvement of this inhibitor in cardiac remod-
eling. As a matter of fact, the response of IDC to LVAD
therapy is of particular interest because the myocardium
is dysfunctional yet viable, unlike end-stage IHD [38].
The involvement of SrpA3 in cardiac remodeling is also
supported by the positive correlations observed among
cathepsin classes and their inhibitors. The strong correl-
ation observed between cathepsins belonging to different
classes, such as CatS and CatG, suggested the possible
presence of synergic effects in cardiac remodeling. Cyst-
eine and serine cathepsins are generally considered as
two different systems: cysteine cathepsins are lysosome
proteases having a role in cardiovascular remodeling,
produced by cardiomyocytes, fibroblast and endothelial
cells [5]; whereas serine proteases are typically known to
be secreted by inflammatory cells such as neutrophils,
macrophages and MCs [10].arkers
CatG CysB CysC SrpA3
rho = 0.30 rho = 0.42 rho = 0.39 rho = 0.58
p = 0.032 p = 0.002 p = 0.003 p < 0.0001
rho = 0.28 rho = 0.22 rho = 0.21 rho = 0.47
p = 0.051 ns ns p = 0.001
rho = −0.10 rho = 0.25 rho = 0.16 rho = 0.15
ns ns ns ns
Figure 5 Cathepsin system and clinical outcome. Correlation
between myocardial SrpA3 (A), CatK (B) and CatS (C) and length of
hospitalization in pre-LVAD patients.
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between CatS, CatK and SrpA3 with the length of
hospitalization was found. These relationships with out-
come could suggest a possible clinical relevance of the
cathepsin system in HF. With regard to risk stratifica-
tion in ESHF-patients, little is known about remodel-
ing/inflammatory profiles and their impact on clinical
outcome and prognosis, and it's reasonable to speculatea role of inflammatory system on the outcome of these
fragile patients. The findings of this study underscore
the importance to consider the remodeling/inflamma-
tory parameters to deepen the knowledge of features of
HF patients and better stratify the operative risk, and
the risk of death after LVAD implantation [39].
Study limitation
The main limitation of this study is the low number of
patients. However, the internal control (HT group) and
the post-LVAD group operated by collecting in the same
patient myocardial tissue at HT time from both LV and
RV allowed a better interpretation of the results in this
limited sample size. Moreover, this low sample size made
difficult to assess the impact of different clinical vari-
ables (i.e., therapies, risk factors, etc.) on the modula-
tion of the cathepsin pathway. Due to the small size of
myocardial biopsies, the activities of Cathepsin and their
inhibitors could not be analyzed and, consequently, func-
tional consequences of their parallel increase could not be
deduced. Previous studies demonstrated that several car-
diac drugs could have inhibitory effects on CatS and CatK
expression in cardiovascular-renal tissues [40,41]. In this
study, the lack of differences in pharmacological treat-
ments among patient groups (Table 1) minimized possible
effects of drugs on expression of cathepsins and inflamma-
tory mediators.
Conclusions
This study takes advantage of cathepsin system evalu-
ation in an in vivo setting represented by a human
model of HF. Our data suggest a parallel activation of
molecules promoting the detrimental effect of ECM deg-
radation such as CatS and CatG, and molecules promot-
ing a positive regulation of cardiac remodeling, such as
cystatins and serpins. Their modifications were associ-
ated with the inflammatory environment occurring after
the device implantation. Determination of the specific
pathways in HF may be essential in order to discover novel
therapeutic strategies. In particular, novel treatment op-
tions may include the use of specific inhibitors for pro-
cesses involved in HF progression such as proteolytic
activities. These data are still of pivotal importance for
understanding the process induced by mechanical heart
unloading. More studies are necessary to better clarify the
role of Cathepsin system in reverse remodeling.
Competing interests
The authors declare that they have no competing interests.Authors ? contributions
Conception and design of the study: CC, ADA, DG. Acquisition of data: all
authors. Analysis and interpretation of data: CC, ADA, DG. Drafting and
critical revision of the article for important intellectual content: all authors.
Final approval of the version to be published: all authors.
D?Amico et al. Journal of Translational Medicine 2014, 12:350 Page 11 of 12
http://www.translational-medicine.com/content/12/1/350Acknowledgements
This study was supported partially by grants from the projects SensorART-A
Remote Controlled SensorizedARTificial Heart Enabling Patients Empowerment
and New Therapy Approaches (FP7-ICT-2009 project, grant agreement 248763).
Author details
1Scuola Superiore Sant ?Anna, Institute of Life Sciences, 56100 Pisa, Italy.
2Laboratory of Cardiovascular Biochemistry, Institute of Clinical Physiology,
Consiglio Nazionale delle Ricerche (CNR), Area della Ricerca ? Via Moruzzi, 1,
56100 Pisa, Italy. 3Cardiovascular Department, Institute of Clinical Physiology,
Consiglio Nazionale delle Ricerche (CNR), Niguarda C? Granda Hospital,
20162 Milan, Italy. 4Cardiovascular Department, Niguarda Ca ? Granda Hospital,
20162 Milan, Italy.
Received: 11 September 2014 Accepted: 2 December 2014
References
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford
ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard
VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH,
Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB,
McGuire DK, Mohler ER 3rd, Moy CS, et al: Heart Disease and Stroke
Statistics? 2014 Update: a report from the American heart association.
Circulation 2014, 129(3):e28? e292.
2. Wilson SR, Givertz MM, Stewart GC, Mudge GH Jr: Ventricular assist devices
the challenges of outpatient management. J Am Coll Cardiol 2009,
54(18):1647? 1659.
3. Hall JL, Fermin DR, Birks EJ, Barton PJ, Slaughter M, Eckman P, Baba HA,
Wohlschlaeger J, Miller LW: Clinical, molecular, and genomic changes in
response to a left ventricular assist device. J Am Coll Cardiol 2011,
57(6):641? 652.
4. Muller AL, Dhalla NS: Role of various proteases in cardiac remodeling and
progression of heart failure. Heart Fail Rev 2012, 17(3):395? 409.
5. Cheng XW, Shi GP, Kuzuya M, Sasaki T, Okumura K, Murohara T: Role for
cysteine protease cathepsins in heart disease: focus on biology and
mechanisms with clinical implication. Circulation 2012, 125(12):1551? 1562.
6. Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, Turk D: Cysteine
cathepsins: from structure, function and regulation to new frontiers.
Biochim Biophys Acta 2012, 1824(1):68 ? 88.
7. Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S: Cathepsin cysteine
proteases in cardiovascular disease. FASEB J 2007, 21:3029 ? 3041.
8. Taglieri N, Koenig W, Kaski JC: Cystatin C and cardiovascular risk.
Clin Chem 2009, 55(11):1932? 1943.
9. Turk B, Turk D, Salvesen GS: Regulating cysteine protease activity:
essential role of protease inhibitors as guardians and regulators.
Curr Pharm Des 2002, 8:1623 ? 1637.
10. Korkmaz B, Moreau T, Gauthier F: Neutrophil elastase, proteinase 3 and
cathepsin G: physicochemical properties, activity and physiopathological
functions. Biochimie 2008, 90(2):227? 242.
11. Horvath AJ, Irving JA, Rossjohn J, Law RH, Bottomley SP, Quinsey NS, Pike
RN, Coughlin PB, Whisstock JC: The murine orthologue of human
antichymotrypsin. A structural paradigm for clade A3 serpins. J Biol Chem
2005, 280(52):43168 ? 43178.
12. W?gs?ter D, Johansson D, Fontaine V , Vorkapic E, B?cklund A, Razuvaev A,
M?yr?np?? MI, Hjerpe C, Caidahl K, Hamsten A, Franco-Cereceda A, Wil-
bertz J, Swedenborg J, Zhou X, Eriksson P: Serine protease inhibitor A3 in
atherosclerosis and aneurysm disease. Int J Mol Med 2012, 30(2):288 ? 294.
13. Tan GJ, Peng ZK, Lu JP, Tang FQ: Cathepsins mediate tumor metastasis.
World J Biol Chem 2013, 4(4):91 ? 101.
14. Chwieralski CE, Welte T, B?hling F: Cathepsin-regulated apoptosis.
Apoptosis 2006, 11:143? 149.
15. Cheng XW, Obata K, Kuzuya M, Izawa H, Nakamura K, Asai E, Nagasaka T,
Saka M, Kimata T, Noda A, Nagata K, Jin H, Shi GP, Iguchi A, Murohara T,
Yokota M: Elastolytic cathepsin induction/activation system exists in
myocardium and is upregulated in hypertensive heart failure.
Hypertension 2006, 48:979 ? 987.
16. Li X, Liu Z, Cheng Z, Cheng X: Cysteinyl cathepsins: multifunctional
enzymes in cardiovascular disease. Chonnam Med J 2012, 48(2):77 ? 85.
17. Reiser J, Adair B, Reinheckel T: Specialized roles for cysteine cathepsins in
health and disease. J Clin Invest 2010, 120:3421 ? 3431.18. Hua Y, Xu X, Shi GP, Chicco AJ, Ren J, Nair S: Cathepsin K knockout
alleviates pressue overload-induced cardiac hypertrophy. Hypertension
2013, 61:1184 ? 1192.
19. Arnl?v J: Cathepsin S as a biomarker: where are we now and what are
the future challenges? Biomark Med 2012, 6(1):9 ? 11.
20. Caselli C, D?Amico A, Caruso R, Cabiati M, Prescimone T, Cozzi L, Cannata A,
Parodi O, Del Ry S, Giannessi D: Impact of normalization strategy on
cardiac expression of pro-inflammatory cytokines: Evaluation of refer-
ence genes in different human myocardial regions after Left Ventricular
Assist Device support. Cytokine 2013, 63(2):113? 122.
21. P?til? T, Kukkonen S, Vento A, Pettil? V, Suojaranta-Ylinen R: Relation of the
Sequential Organ Failure Assessment score to morbidity and mortality
after cardiac surgery. Ann Thorac Surg 2006, 82:2072 ? 2078.
22. Caruso R, Verde A, Cabiati M, Milazzo F, Boroni C, Del Ry S, Parolini M,
Vittori C, Paino R, Martinelli L, Giannessi D, Frigerio M, Parodi O:
Association of pre-operative interleukin-6 levels with Interagency
Registry for Mechanically Assisted Circulatory Support profiles and
intensive care unit stay in left ventricular assist device patients. J Heart
Lung Transplant 2012, 31:625 ? 633.
23. Bustin SA: Why the need for qPCR publication guidelines? ? the case for
MIQE. Methods 2010, 50(4):217? 226.
24. Caselli C, D'Amico A, Ragusa R, Caruso R, Prescimone T, Cabiati M, Nonini S,
Marraccini P, Del Ry S, Trivella MG, Parodi O, Giannessi D: IL-33/ST2
pathway and classical cytokines in end-stage heart failure patients
submitted to left ventricular assist device support: a paradoxic role for
inflammatory mediators? Mediators Inflamm 2013, 2013:498703.
25. Cheng XW, Kuzuya M, Sasaki T, Arakawa K, Kanda S, Sumi D, Koike T, Maeda
K, Tamaya-Mori N, Shi GP, Saito N, Iguchi A: Increased expression of
elastolytic cysteine proteases, cathepsin S and K, in the neointima of
ballon-injured rat carotid arteries. Am J Pathol 2004, 164:243 ? 251.
26. Jiang H, Cheng XW, Shi GP, Hu L, Inoue A, Yamamura Y, Wu H, Takeshita K, Li
X, Huang Z, Song H, Asai M, Hao CN, Unno K, Koike T, Oshida Y, Okumura K,
Murohara T, Kuzuya M: Cathepsin K-mediated Notch1 activation contributes
to neovascularization in response to hypoxia. Nat Commun 2014, 5:3838.
27. Hu L, Cheng XW, Song H, Inoue A, Jiang H, Li X, Shi GP, Kozawa E, Okumura
K, Kuzuya M: Cathepsin K activity controls injury-related vascular repair in
mice. Hypertension 2014, 63(3):607? 615.
28. Jahanyar J, Youker KA, Loebe M, Assad-Kottner C, Koerner MM, Torre-Amione
G, Noon GP: Mast cell-derived cathepsin G: a possible role in the adverse re-
modeling of the failing human heart. J Surg Res 2007, 140(2):199? 203.
29. Rafiq K, Hanscom M, Valerie K, Steinberg SF, Sabri A: Novel mode for
neutrophil protease cathepsin G-mediated signaling: membrane shed-
ding of epidermal growth factor is required for cardiomyocyte anoikis.
Circ Res 2008, 102(1):32 ? 41.
30. Xu JM, Shi GP: Emerging role of mast cells and macrophages in
cardiovascular and metabolic diseases. Endocr Rev 2012, 33(1):71 ? 108.
31. Shiota N, Rysa J, Kovanen PT, Ruskoaho H, Kokkonen JO, Lindstedt KA:
A role for cardiac mast cells in the pathogenesis of hypertensive heart
disease. J Hypertens 2003, 21:1935.
32. Lu H, Mel?ndez GC, Levick SP, Janicki JS: Prevention of adverse cardiac
remodeling to volume overload in female rats is the result of an
estrogen-altered mast cell phenotype. Am J Physiol Heart Circ Physiol 2012,
302(3):H811 ? H817.
33. Palaniyandi SS, Inagaki K, Mochly-Rosen D: Mast cells and epsilonPKC: a
role in cardiac remodeling in hypertension-induced heart failure. J Mol
Cell Cardiol 2008, 45(6):779? 786.
34. Jiang B, Liao R: The paradoxical role of inflammation in cardiac repair
and regeneration. J Cardiovasc Transl Res 2010, 3:410 ? 416.
35. Petermann I, Mayer C, Stypmann J, Biniossek ML, Tobin DJ, Engelen MA,
Dandekar T, Grune T, Schild L, Peters C, Reinheckel T: Lysosomal,
cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L
knockout mice. FASEB J 2006, 20:1266 ? 1268.
36. Sun M, Chen M, Liu Y, Fukuoka M, Zhou K, Li G, Dawood F, Gramolini A, Liu
PP: Cathepsin-L contributes to cardiac repair and remodelling
post-infarction. Cardiovasc Res 2010, 89:374? 383.
37. Bengtsson E, To F, H?kansson K, Grubb A, Br?n?n L, Nilsson J, Jovinge S:
Lack of cysteine protease inhibitor cystatin C promotes atherosclerosis
in apolipoprotein E-deficient mice. Arterioscl Thromb Vasc Biol 2005,
25:2151? 2156.
38. Butler CR, Jugdutt BI: The paradox of left ventricular assist device
unloading and myocardial recovery in end-stage dilated
D?Amico et al. Journal of Translational Medicine 2014, 12:350 Page 12 of 12
http://www.translational-medicine.com/content/12/1/350cardiomyopathy: implications for heart failure in the elderly. Heart Fail
Rev 2012, 17(4 ? 5):615? 633.
39. Caruso R, Botta L, Verde A, Milazzo F, Vecchi I, Trivella MG, Martinelli L, Paino
R, Frigerio M, Parodi O: Relationship between pre-implant interleukin-6
levels, inflammatory response, and early outcome in patients supported
by left ventricular assist device: a prospective study. PLoS One 2014,
9(3):e90802.
40. Qin YW, Ye P, He JQ, Sheng L, Wang LY, Du J: Simvastatin inhibited
cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a
? Western-style diet ? by increasing PPAR α and γ expression and reducing
TC, MMP-9, and Cat S levels. Acta Pharmacol Sin 2010, 31(10):1350? 1358.
41. Cheng XW, Kuzuya M, Sasaki T, Inoue A, Hu L, Song H, Huang Z, Li P,
Takeshita K, Hirashiki A, Sato K, Shi GP, Okumura K, Murohara T: Inhibition
of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-
3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin. J Hypertens
2011, 29(3):542? 552.
doi:10.1186/s12967-014-0350-7
Cite this article as: D?Amico et al.: Uncovering the cathepsin system in
heart failure patients submitted to Left Ventricular Assist Device (LVAD)
implantation. Journal of Translational Medicine 2014 12:350.Submit your next manuscript to BioMed Central
and take full advantage of: 
? Convenient online submission
? Thorough peer review
? No space constraints or color ?gure charges
? Immediate publication on acceptance
? Inclusion in PubMed, CAS, Scopus and Google Scholar
? Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
